These studies demonstrate that immunotherapeutic antibodies have the potential to alter the functioning of PD-L1/PD-1 and may induce other pathways through which tumor cells generate resistance against targeted PD-1/PD-L1 therapy (Hamanishi et al., 2016). The gene discussed is CD274; the disease is neoplasm.